Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00467259 · ClinicalTrials.gov registry record · Phase 3
Endometrial Safety Study of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal Women
A Phase 3 study, sponsored by Warner Chilcott.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,271
- Enrollment target
NCT00467259 is a Phase 3 study that has completed, run by Warner Chilcott. The registered enrollment target is 1,271 participants.
The verdict
NCT00467259, a Phase 3 study, has completed, sponsored by Warner Chilcott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,271 participants
- Enrollment target
Study Summary
This study is designed to evaluate the endometrial safety of a testosterone patch as treatment for low libido in naturally postmenopausal women.
Interventions
- DRUG Placebo patch
- DRUG Testosterone Transdermal System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,271 participants |
| Start Date | 2007-04 |
| Est. Completion | 2009-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00467259
The ClinicalTrials.gov registry entry for NCT00467259 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,271 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Warner Chilcott, which has 53 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo patch is the first listed.
NCT00467259 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00467259 about?
NCT00467259 is a clinical study titled "Endometrial Safety Study of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal Women". This study is designed to evaluate the endometrial safety of a testosterone patch as treatment for low libido in naturally postmenopausal women.
What is the current status of trial NCT00467259?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,271 participants. The study started on 2007-04. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00467259?
The interventions under investigation include: Placebo patch (DRUG), Testosterone Transdermal System (DRUG).
Who is sponsoring clinical trial NCT00467259?
This trial is sponsored by Warner Chilcott, which has 53 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.